Associations between the expression of ISGs or IFN-λ3 and treatment efficacy.

<p>Patients were divided into three groups according to <i>IL28B</i> genotype at rs8099917 and treatment outcome: TT; SVR (n = 31), TG/GG; SVR (n = 13), and TG/GG; non-SVR (n = 6). (A) Expression of <i>ISG15, IL28B</i> and suppressive genes in PBMCs at 8 hours after the initial administration of pegylated interferon, ribavirin, plus NS3/4A protease inhibitor in each group. (B) Fold-changes of mRNAs including suppressive genes at 8 hours relative to baseline in each group. Levels of mRNAs including suppressive genes and <i>ISG15</i> were normalized against glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and those for <i>IL28B</i> were measured using the calibration curves of cDNA clone. TT and TG/GG at rs8099917 is a favorable and an unfavorable <i>IL28B</i> genotype for treatment responses, respectively. Boxes represent the interquartile range of the data. The lines across the boxes and the numbers indicate the median values. The hash marks above and below the boxes indicate the 90th and 10th percentiles for each group, respectively.